oxadiazoles and Neonatal-Sepsis

Neonatal enterovirus sepsis has high mortality. Antiviral therapy is not available.. Neonates with suspected enterovirus sepsis (hepatitis, coagulopathy, and/or myocarditis) with onset at ≤15 days of life were randomized 2:1 to receive oral pleconaril or placebo for 7 days. Serial virologic (oropharynx, rectum, urine, serum), clinical, pharmacokinetic, and safety evaluations were performed.. Sixty-one subjects were enrolled (43 treatment, 18 placebo), of whom 43 were confirmed enterovirus infected (31 treatment, 12 placebo). There was no difference in day 5 oropharyngeal culture positivity (primary endpoint; 0% in both groups). However, enterovirus-infected subjects in the treatment group became culture negative from all anatomic sites combined faster than placebo group subjects (median 4.0 versus 7.0 days, P = .08), and fewer subjects in the treatment group remained polymerase chain reaction (PCR)-positive from the oropharynx when last sampled (23% versus 58%, P = .02; median, 14.0 days). By intent to treat, 10/43 (23%) subjects in the treatment group and 8/18 (44%) in the placebo group died (P = .02 for 2-month survival difference); among enterovirus-confirmed subjects, 7/31 (23%) in the treatment group died versus 5/12 (42%) in the placebo group (P = .26). All pleconaril recipients attained concentrations greater than the IC90 after the first study day, but 38% were less than the IC90 during the first day of treatment. One subject in the treatment group and three in the placebo group had treatment-related adverse events.. Shorter times to culture and PCR negativity and greater survival among pleconaril recipients support potential efficacy and warrant further evaluation.

Topics: Antiviral Agents; Double-Blind Method; Enterovirus; Enterovirus Infections; Female; Humans; Infant; Infant, Newborn; Male; Neonatal Sepsis; Oropharynx; Oxadiazoles; Oxazoles; Rectum

Topics: Antiviral Agents; Double-Blind Method; Enterovirus Infections; Female; Humans; Infant, Newborn; Male; Neonatal Sepsis; Oxadiazoles; Oxazoles; Placebo Effect; Reproducibility of Results; Time Factors; Treatment Outcome